Anthony M Norcia1, Alexandra Yakovleva2, Naz Jehangir2, Jeffrey L Goldberg2. 1. Department of Psychology, Wu Tsai Neurosciences Institute, Stanford University, Stanford, California, United States. 2. Spencer Center for Vision Research, Byers Eye Institute, Department of Ophthalmology, Stanford University, Stanford, California, United States.
Abstract
Purpose: The purpose of this study was to determine whether glaucoma in human patients produces preferential damage to OFF visual pathways, as suggested by animal experimental models, patient electroretinogram (ERG), and retinal imaging data. Methods: Steady-state visual evoked potentials (SSVEPs) were recorded monocularly from 50 patients with glaucoma and 28 age-similar controls in response to equal Weber contrast increments and decrements presented using 2.73 hertz (Hz) sawtooth temporal waveforms. Results: The eyes of patients with glaucoma were separated into mild (better than -6 decibel [dB] mean deviation; n = 28) and moderate to severe (worse than -6 dB mean deviation, n = 22) groups based on their Humphrey 24-2 visual field measurements. Response amplitudes and phases from the two glaucoma-severity groups were compared to controls at the group level. SSVEP amplitudes were depressed in both glaucoma groups, more so in the moderate to severe glaucoma group. The differences between controls and the moderate-severe glaucoma groups were more statistically reliable for decrements than for increments. Mean responses to decremental sawtooth stimuli were larger than those to increments in controls and in the mild glaucoma but not in the moderate to severe glaucoma group at the first harmonic. OFF/decrement responses at the first harmonic were faster in controls, but not in patients. Conclusions: The observed pattern of preferential loss of decremental responses in human glaucoma is consistent with prior reports of selective damage to OFF retinal ganglion cells in murine models and in data from human ERG and retinal imaging. These data motivate pursuit of SSVEP as a biomarker for glaucoma progression.
Purpose: The purpose of this study was to determine whether glaucoma in human patients produces preferential damage to OFF visual pathways, as suggested by animal experimental models, patient electroretinogram (ERG), and retinal imaging data. Methods: Steady-state visual evoked potentials (SSVEPs) were recorded monocularly from 50 patients with glaucoma and 28 age-similar controls in response to equal Weber contrast increments and decrements presented using 2.73 hertz (Hz) sawtooth temporal waveforms. Results: The eyes of patients with glaucoma were separated into mild (better than -6 decibel [dB] mean deviation; n = 28) and moderate to severe (worse than -6 dB mean deviation, n = 22) groups based on their Humphrey 24-2 visual field measurements. Response amplitudes and phases from the two glaucoma-severity groups were compared to controls at the group level. SSVEP amplitudes were depressed in both glaucoma groups, more so in the moderate to severe glaucoma group. The differences between controls and the moderate-severe glaucoma groups were more statistically reliable for decrements than for increments. Mean responses to decremental sawtooth stimuli were larger than those to increments in controls and in the mild glaucoma but not in the moderate to severe glaucoma group at the first harmonic. OFF/decrement responses at the first harmonic were faster in controls, but not in patients. Conclusions: The observed pattern of preferential loss of decremental responses in human glaucoma is consistent with prior reports of selective damage to OFF retinal ganglion cells in murine models and in data from human ERG and retinal imaging. These data motivate pursuit of SSVEP as a biomarker for glaucoma progression.
Authors: Luca Della Santina; Denise M Inman; Caroline B Lupien; Philip J Horner; Rachel O L Wong Journal: J Neurosci Date: 2013-10-30 Impact factor: 6.167
Authors: Folkert K Horn; Kristina Gottschalk; Christian Y Mardin; Gobinda Pangeni; Anselm G Jünemann; Jan Kremers Journal: Doc Ophthalmol Date: 2011-01-26 Impact factor: 2.379
Authors: Michael L Risner; Silvia Pasini; Melissa L Cooper; Wendi S Lambert; David J Calkins Journal: Proc Natl Acad Sci U S A Date: 2018-02-20 Impact factor: 11.205
Authors: Zeinab Ghassabi; Roman V Kuranov; Joel S Schuman; Ronald Zambrano; Mengfei Wu; Mengling Liu; Behnam Tayebi; Yuanbo Wang; Ian Rubinoff; Xiaorong Liu; Gadi Wollstein; Hao F Zhang; Hiroshi Ishikawa Journal: Invest Ophthalmol Vis Sci Date: 2022-01-03 Impact factor: 4.799